Advertisement
Home »

The Impact of a Multidisciplinary Tumor Board (MTB) on Treatment Decision Making for Patients With Renal Cell Carcinoma (RCC): 5-Year Data Analysis.

Feb 26, 2024

ABOUT THE EXPERTS

  • Luna van den Brink

    Department of Urology, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands; Department of Urology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands. Electronic address: l.vandenbrink@amsterdamumc.nl.

    Annebeth E C Ruiter

    OLVG (Onze Lieve Vrouwe Gasthuis), Department of Urology, Amsterdam, The Netherlands.

    Brunolf W Lagerveld

    OLVG (Onze Lieve Vrouwe Gasthuis), Department of Urology, Amsterdam, The Netherlands.

    Niels M Graafland

    Department of Urology, Netherlands Cancer Institute (NKI), Amsterdam, The Netherlands.

    Axel Bex

    Department of Urology, Netherlands Cancer Institute (NKI), Amsterdam, The Netherlands; Department of Urology, Royal Free Hospital, London, United Kingdom.

    Harrie P Beerlage

    Department of Urology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands.

    Jeroen R A van Moorselaar

    Department of Urology, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands.

    Patricia J Zondervan

    Department of Urology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands.

REFERENCES & ADDITIONAL READING

PubMed

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

Advertisement